Recent concerns surrounding HRT.
Millions of women are treated with hormone replacement therapy (HRT) for relief of menopausal symptoms, including vasomotor flushes and sweats for which oestrogen is uniquely and highly effective. Others may continue longer-term treatment in the hope that HRT will help to prevent chronic disease. The preservation of bone mass with continuing oestrogen therapy and reduction of subsequent risk of fracture is well established. Observational studies of the metabolic and vascular effects of oestrogens have suggested a potential benefit in reducing the risk of vascular disease, but recently published randomized controlled trials demonstrate no evidence of benefit in women with established vascular disease or in apparently healthy women. The increased risks of breast cancer and thromboembolic disease have been confirmed in these trials, with evidence of increased risk of stroke. Observational data suggest there may be a small increased risk of ovarian cancer associated with longer-term use of HRT. The premature termination of one arm of the Women's Health Initiative randomized controlled trial caused concern among patients, doctors and pharmaceutical companies. There are difficulties in extrapolating the results from trials using a specific HRT product to advise women on the wide range of other hormone products, doses, combinations and routes of administration. However, in the absence of evidence that other products are safer, the data suggest that for many women the risks associated with long-term use of HRT outweigh the benefits. There are nonhormonal strategies for the prevention and treatment of osteoporosis. HRT is not, and has never been, licensed in the UK for the prevention or treatment of vascular disease, and the data suggesting potential benefit should now be regarded as biased. The absolute incidence of an adverse event is low, and the risk in an individual woman in a single year is very small, but the risks are cumulative over time with long-term use. The risk-benefit balance of each woman needs regular reappraisal with continued use.
Armitage
Mary
M
Bournemouth Diabetic and Endocrine Centre, Royal Bournemouth Hospital, Dorset, UK. mary.armitage@rbch-tr.swest.nhs.uk
Nooney
Janet
J
Evans
Stephen
S
D000544:Alzheimer Disease / Q000517:prevention & control; D001943:Breast Neoplasms / Q000139:chemically induced; D003110:Colonic Neoplasms / Q000517:prevention & control; D003327:Coronary Disease / Q000517:prevention & control; D016889:Endometrial Neoplasms / Q000139:chemically induced; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005260:Female; D019584:Hot Flashes / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000139:chemically induced*; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D010051:Ovarian Neoplasms / Q000139:chemically induced; D011372:Progestins / Q000009:adverse effects* / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000139:chemically induced; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D020521:Stroke / Q000139:chemically induced; D017211:Treatment Failure; D020246:Venous Thrombosis / Q000139:chemically induced
D011372:Progestins